This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Patients with seronegative myasthenia gravis (MG) often harbor antibodies for muscle-specific tyrosine kinase (MuSK).1 Nonresponsiveness or poor tolerability of anticholinesterase therapy has been mentioned in reports of this population2,3 but not comprehensively studied. We report anticholinesterase nonresponsiveness in 14 MuSK-antibody (Ab) positive patients seen at the University of Alabama at Birmingham (UAB) and University of Texas Southwestern Medical Center (UTSW), comparing them to MuSK-Ab-negative and acetylcholine receptor (AChR)-Ab seropositive patients from the UAB.
Methods.
Anticholinesterase hypersensitivity was defined when myasthenic symptoms worsened with medication; anticholinesterase intolerance when the patient developed severe cholinergic side effects with small doses of pyridostigmine or edrophonium, even with the administration of atropine or glycopyrrolate; and no improvement when there was no clinical benefit following administration of pyridostigmine. Hypersensitivity, intolerance, and no improvement were grouped together as anticholinesterase nonresponsiveness.
Results.
At UAB, the AChR-Ab test was positive in 73 (72%) of 102 patients with generalized MG; the MuSK antibody test was positive in 7 (24%) of the …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis
Anti-MuSK antibodies: Correlation with myasthenia gravis severity
Ocular vestibular evoked myogenic potentials as a test for myasthenia gravis
Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis